NTHI
NEONC TECHNOLOGIES HOLDINGS, INC.
NASDAQ · Healthcare · Biotechnology · US
$2.72
+0.74%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.77
From 52W high−77.01%
Volume106945.00
Market cap$78.35M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.77
From 52W high
−77.01%
Volume
106945.00
Market cap
$78.35M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
P/E (TTM)
—
RSI (14)
42.7
MomentumView details →
1D Return
+0.74%
YTD Return
−65.90%
SummaryUpdated Jun 1, 2026
Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) is an early-stage biotechnology company founded in 2023 and headquartered in Los Angeles, California. The company went public in March 2025 through an initial public offering. Neonc focuses on developing innovative molecular technologies designed to enhance the targeted delivery of therapeutic agents for treating central nervous system diseases, particularly brain cancers. As a clinical-stage biotech company, Neonc is currently advancing its lead drug candidates through various phases of clinical trials while burning through cash to fund research and development activities.
Similar companies
Latest newsMore news →
NEONC TECHNOLOGIES HOLDINGS, INC. said Steven L. Giannotta resigned as a Class I director and Ali Mohammad Ahmad Alabedin was appointed a director, effective October 9, 2026.4d agoNeOnc is scheduled to meet with the FDA for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212.22d agoNeOnc Technologies Holdings redeemed all 6,000 outstanding shares of its Series A Convertible Preferred Stock for cash at an aggregate stated value of $6.0 million.33d ago